Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTXNASDAQ:DRUGNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriaCell Therapeutics$4.46-2.8%$4.09$3.00▼$36.60$17.03M1.34480,183 shs448,029 shsDRUGBright Minds Biosciences$30.70-0.6%$33.54$0.93▼$79.02$216.25M-5.5823,967 shs39,140 shsRXRXRecursion Pharmaceuticals$5.59-2.3%$6.02$3.79▼$12.36$2.30B112.36 million shs14.86 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriaCell Therapeutics-8.20%-14.21%+15.62%-22.20%-85.83%DRUGBright Minds Biosciences-4.01%-7.79%-15.37%+3.45%+2,747.00%RXRXRecursion Pharmaceuticals-2.05%+1.60%-1.55%-20.11%-30.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriaCell Therapeutics1.5897 of 5 stars3.52.00.00.01.60.00.6DRUGBright Minds Biosciences3.309 of 5 stars3.65.00.00.03.62.50.0RXRXRecursion Pharmaceuticals2.2146 of 5 stars3.22.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriaCell Therapeutics 3.00Buy$32.00617.49% UpsideDRUGBright Minds Biosciences 3.20Buy$84.33174.70% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$8.2046.69% UpsideCurrent Analyst Ratings BreakdownLatest BCTX, DRUG, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/10/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.004/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.002/28/2025RXRXRecursion PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/28/2025RXRXRecursion PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.002/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.002/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.002/3/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $32.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriaCell TherapeuticsN/AN/AN/AN/A($2.20) per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/ARXRXRecursion Pharmaceuticals$58.49M38.42N/AN/A$1.98 per share2.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriaCell Therapeutics-$4.79M-$5.03N/AN/AN/AN/AN/A-191.19%6/13/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.17N/AN/AN/AN/A-5.85%-5.68%5/21/2025 (Estimated)RXRXRecursion Pharmaceuticals-$328.07M-$1.66N/AN/AN/A-579.52%-76.56%-55.68%5/5/2025 (Estimated)Latest BCTX, DRUG, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/ADRUGBright Minds Biosciences-$0.38N/AN/AN/AN/AN/A5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44N/AN/AN/A$18.12 millionN/A3/17/2025Q2 2025BCTXBriaCell Therapeutics-$1.94-$2.33-$0.39-$2.33N/AN/A2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 million2/13/2025Q1 2025DRUGBright Minds Biosciences-$0.23$0.01+$0.24$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriaCell TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriaCell TherapeuticsN/A1.651.65DRUGBright Minds BiosciencesN/A126.0111.31RXRXRecursion Pharmaceuticals0.044.354.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriaCell Therapeutics15.42%DRUGBright Minds Biosciences40.52%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipBCTXBriaCell Therapeutics5.73%DRUGBright Minds Biosciences42.66%RXRXRecursion Pharmaceuticals15.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriaCell Therapeutics83.71 million3.50 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableRXRXRecursion Pharmaceuticals400401.99 million329.18 millionOptionableBCTX, DRUG, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - Should You Buy?April 30 at 3:36 PM | marketbeat.comWas Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?April 29 at 10:20 AM | finance.yahoo.comBarclays PLC Has $4.28 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 29 at 3:51 AM | marketbeat.comRecursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth KnowingApril 28 at 6:55 PM | zacks.comRecursion to Report First Quarter 2025 Business Updates and Financial Results on May 5thApril 28 at 8:27 AM | globenewswire.combluebird bio (NASDAQ:BLUE) and Recursion Pharmaceuticals (NASDAQ:RXRX) Critical AnalysisApril 27 at 2:27 AM | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.3% Higher - Should You Buy?April 26, 2025 | marketbeat.comLegal & General Group Plc Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 26, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 1.9% - Still a Buy?April 25, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.5% - What's Next?April 24, 2025 | marketbeat.comWells Fargo & Company MN Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 24, 2025 | marketbeat.comRecursion to present clinical data from ongoing Phase 1b/2 trial of REC-4881April 24, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 3.2% - Time to Buy?April 23, 2025 | marketbeat.com3 Monster Stocks to Hold for the Next 10 YearsApril 23, 2025 | fool.comRecursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025April 22, 2025 | globenewswire.comRecursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should KnowApril 21, 2025 | msn.comWhich Is a Better Investment, Alvotech or Recursion Pharmaceuticals, Inc. Stock?April 21, 2025 | aaii.comRockefeller Capital Management L.P. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 21, 2025 | marketbeat.comNan Fung Group Holdings Ltd Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 20, 2025 | marketbeat.comInvestment strategist picks 3 ‘new age' healthcare stocks to buyApril 20, 2025 | finbold.comXTX Topco Ltd Invests $565,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)April 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy3 Momentum Stocks That Could Soar Post-Market VolatilityBy Nathan Reiff | April 21, 2025View 3 Momentum Stocks That Could Soar Post-Market VolatilityViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsCan Solid Biosciences Challenge Sarepta in the DMD Market?By Leo Miller | April 8, 2025View Can Solid Biosciences Challenge Sarepta in the DMD Market?BCTX, DRUG, and RXRX Company DescriptionsBriaCell Therapeutics NASDAQ:BCTX$4.46 -0.13 (-2.83%) As of 04:00 PM EasternBriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Bright Minds Biosciences NASDAQ:DRUG$30.70 -0.19 (-0.62%) As of 04:00 PM EasternBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Recursion Pharmaceuticals NASDAQ:RXRX$5.59 -0.13 (-2.27%) As of 04:00 PM EasternRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
